First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
Published online on June 02, 2026
Abstract
Journal of Child Neurology, Ahead of Print.
B-cell depletion is increasingly used in pediatric-onset multiple sclerosis (POMS), but data on rituximab as first-line chronic therapy remain limited. We retrospectively reviewed 17 children with POMS who received rituximab as their initial long-term ...
B-cell depletion is increasingly used in pediatric-onset multiple sclerosis (POMS), but data on rituximab as first-line chronic therapy remain limited. We retrospectively reviewed 17 children with POMS who received rituximab as their initial long-term ...